Abstract
ClinicalTrials.gov, NCT03625531. Registered on July 13, 2018. Chinese Clinical Trial Registry, ChiCTR1800017304. Registered on July 23, 2018.
Introduction
Polycystic Ovary Syndrome (PCOS) is a leading cause of female infertility, characterized by irregular ovulation and hormonal imbalances. While letrozole (an aromatase inhibitor) is the current first-line pharmacological treatment, it does not necessarily reduce pregnancy complications or miscarriages. Acupuncture is a popular alternative, but previous large-scale trials have yielded conflicting results.
A major criticism of previous trials is their use of "fixed" acupuncture protocols—applying the same needle points to every patient. This contradicts the core philosophy of Traditional Chinese Medicine (TCM), which relies on "syndrome differentiation" to tailor treatments to an individual’s specific physiological state. This multicenter randomized controlled trial (RCT) is designed to determine if personalizing acupuncture based on traditional diagnostic patterns improves clinical outcomes compared to a standardized approach or pharmacological intervention.
Methods and Study Design
The study is an assessor-blinded, four-arm RCT involving 28 hospitals across China. A total of 1,100 participants, aged 20–40 and diagnosed with PCOS via the Rotterdam criteria, are randomly allocated into four groups:
- Personalized Acupuncture: Treatment tailored to TCM diagnoses (e.g., Spleen-yang vs. Liver-yin deficiency). This protocol includes the use of moxibustion (heat therapy).
- Fixed Acupuncture: A standardized set of acupoints used in previous studies.
- Letrozole: Active pharmacological treatment (2.5–7.5 mg daily).
- Placebo Letrozole: A control group receiving inactive pills.
The intervention lasts 16 weeks. To maintain rigor, the study uses a web-based management system (ResMan) for randomization and ensures that outcome assessors and statisticians remain blinded to group assignments.
Key Insights and Hypotheses
The trial serves as a direct test of whether the "art" of TCM diagnosis adds measurable value over standardized protocols. By including letrozole, the study compares acupuncture not just to a placebo, but to the current gold standard of Western medicine.
Beyond live birth rates, the researchers hypothesize that personalized acupuncture may be superior in maintaining pregnancy (reducing miscarriage rates) compared to letrozole. The protocol provides a detailed mapping of TCM "syndromes" to specific acupoints and needling techniques (tonifying vs. sedating), creating a reproducible model for personalized medicine.
Expected Outcomes and Significance
The primary outcome is the live birth rate, defined as the delivery of a viable infant after 28 weeks. Secondary metrics include ovulation rate, hormonal profiles (testosterone, FSH, LH), and quality-of-life scores. Based on previous data, the study is powered to detect clinically significant differences between the four arms. The authors predict a hierarchy of effectiveness: Letrozole > Personalized Acupuncture > Fixed Acupuncture > Placebo.
If the results demonstrate that personalized acupuncture is significantly more effective than fixed protocols, it could shift the integration of acupuncture in fertility clinics globally, moving away from "one-size-fits-all" kits toward diagnostic-led care.
Summary updated